In the middle of the last century, Dr. Sherwood Larence (New York immunologist) discovered tiny molecules in human leukocytes that were able to transmit an immune response to an uninfected human. Since then, the transfer factors named after Larence have been the subject of worldwide scientific research and since 1969 TF has been used in therapy. It is now known that the immunologically active component in TF is localized in T lymphocytes and has a definite, non-specific immunological effect in humans due to its stimulating effect on the cell-mediated immune system. TF has a particular effect on the immunological balance of the T-helper subunits (the TH1 and TH2 lymphocytes) and on the activity of natural killer cells (NK cells).
The extraction of TF from human blood is very expensive, and since 1999 TF has been extracted from bovine colostrum and egg yolk. Since then, extensive clinical experience has been gained and thousands of scientific studies have been conducted. The largest study was conducted by the Moscow Medical Institute and comes to the same conclusion as the independent studies of American institutes.
The immunological mode of action of the transfer factors in Detail:
– Stimulating effect on lymphopoetic stem cells
– Stimulating effect on monocytes and granulocytes,
– stimulation of phagocytosis activity
– Stimulating effect on CD4 cells and CD8 cells.
– equilibrium regulation of TH1 cells and TH2 cells
– Activation of NK cells